HEOR

News

NICE expands cover for AZ's high potassium drug Lokelma

NICE has recommended extending funding via the NHS for AstraZeneca's elevated potassium therapy Lokelma in new guidance, making it easier to receive the drug outside hospital settings.

News

After a Scottish aye, NICE says no to Lynparza for prostate ...

AstraZeneca's PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, according to cost effectiveness agency NICE.<

News

NICE backs Aimmune's peanut allergy drug Palforzia for child...

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla

News

Samantha Roberts to replace Gillian Leng as CEO of NICE

Prof Gillian Leng's replacement as chief executive of the National Institute for Health and Care Excellence (NICE) has been named as Dr Samantha Roberts, currently managing director for hea

News

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

After three years of availability via the Cancer Drugs Fund (CDF), MSD's checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to pr

News

Wales is first UK country to fund GW's Epidyolex for tuberou...

Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by